A hepatitis B- és D-vírus-fertozés diagnosztikája, antivirális kezelése

Horváth Gábor, Gerlei Zsuzsanna, Gervain Judit, G. Lengyel, Makara Mihály, A. Pár, Rókusz László, F. Szalay, Tornai István, Werling Klára, B. Hunyady

Research output: Article

1 Citation (Scopus)

Abstract

Diagnosis and treatment of hepatitis B virus (HBV) and hepatitis D virus infection mean for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while the society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms from 22 September 2017 set by a consensus meeting of physicians involved in the treatment of these diseases. The prevalence of HBV infection in the Hungarian general population is 0,5-0,7%. The indications of treatment are based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for a costeffective approach, the guideline stresses the importance of quick and detailed virologic evaluations, the applicability of transient elastography as an acceptable alternative of liver biopsy in this regard as well as the relevance of appropriate consistent follow-up schedule for viral response during therapy. The first choice of therapy in chronic HBV infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Lamivudine is no longer the first choice; patients currently taking lamivudine must switch if the response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection.

Original languageHungarian
Pages (from-to)24-37
Number of pages14
JournalOrvosi Hetilap
Volume159
DOIs
Publication statusPublished - febr. 1 2018

Fingerprint

Chronic Hepatitis D
Chronic Hepatitis B
Virus Diseases
Hepatitis B virus
Therapeutics
Lamivudine
Tenofovir
Interferons
Hepatitis D
Guidelines
Hepatitis Delta Virus
Elasticity Imaging Techniques
Immunosuppressive Agents
Hepatitis B Surface Antigens
Life Expectancy
Nucleic Acids
Appointments and Schedules

Keywords

  • Adefovir
  • Cirrhosis
  • Entecavir
  • Hepatitis B virus
  • Hepatitis D virus
  • Interferon
  • Lamivudine
  • Liver cancer
  • Pegylated interferon
  • Tenofovir
  • Viral hepatitis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A hepatitis B- és D-vírus-fertozés diagnosztikája, antivirális kezelése. / Gábor, Horváth; Zsuzsanna, Gerlei; Judit, Gervain; Lengyel, G.; Mihály, Makara; Pár, A.; László, Rókusz; Szalay, F.; István, Tornai; Klára, Werling; Hunyady, B.

In: Orvosi Hetilap, Vol. 159, 01.02.2018, p. 24-37.

Research output: Article

Gábor, Horváth ; Zsuzsanna, Gerlei ; Judit, Gervain ; Lengyel, G. ; Mihály, Makara ; Pár, A. ; László, Rókusz ; Szalay, F. ; István, Tornai ; Klára, Werling ; Hunyady, B. / A hepatitis B- és D-vírus-fertozés diagnosztikája, antivirális kezelése. In: Orvosi Hetilap. 2018 ; Vol. 159. pp. 24-37.
@article{7e5978f12b094251b176a18b69880684,
title = "A hepatitis B- {\'e}s D-v{\'i}rus-fertoz{\'e}s diagnosztik{\'a}ja, antivir{\'a}lis kezel{\'e}se",
abstract = "Diagnosis and treatment of hepatitis B virus (HBV) and hepatitis D virus infection mean for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while the society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms from 22 September 2017 set by a consensus meeting of physicians involved in the treatment of these diseases. The prevalence of HBV infection in the Hungarian general population is 0,5-0,7{\%}. The indications of treatment are based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for a costeffective approach, the guideline stresses the importance of quick and detailed virologic evaluations, the applicability of transient elastography as an acceptable alternative of liver biopsy in this regard as well as the relevance of appropriate consistent follow-up schedule for viral response during therapy. The first choice of therapy in chronic HBV infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Lamivudine is no longer the first choice; patients currently taking lamivudine must switch if the response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection.",
keywords = "Adefovir, Cirrhosis, Entecavir, Hepatitis B virus, Hepatitis D virus, Interferon, Lamivudine, Liver cancer, Pegylated interferon, Tenofovir, Viral hepatitis",
author = "Horv{\'a}th G{\'a}bor and Gerlei Zsuzsanna and Gervain Judit and G. Lengyel and Makara Mih{\'a}ly and A. P{\'a}r and R{\'o}kusz L{\'a}szl{\'o} and F. Szalay and Tornai Istv{\'a}n and Werling Kl{\'a}ra and B. Hunyady",
year = "2018",
month = "2",
day = "1",
doi = "10.1556/650.2018.31004",
language = "Hungarian",
volume = "159",
pages = "24--37",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",

}

TY - JOUR

T1 - A hepatitis B- és D-vírus-fertozés diagnosztikája, antivirális kezelése

AU - Gábor, Horváth

AU - Zsuzsanna, Gerlei

AU - Judit, Gervain

AU - Lengyel, G.

AU - Mihály, Makara

AU - Pár, A.

AU - László, Rókusz

AU - Szalay, F.

AU - István, Tornai

AU - Klára, Werling

AU - Hunyady, B.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Diagnosis and treatment of hepatitis B virus (HBV) and hepatitis D virus infection mean for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while the society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms from 22 September 2017 set by a consensus meeting of physicians involved in the treatment of these diseases. The prevalence of HBV infection in the Hungarian general population is 0,5-0,7%. The indications of treatment are based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for a costeffective approach, the guideline stresses the importance of quick and detailed virologic evaluations, the applicability of transient elastography as an acceptable alternative of liver biopsy in this regard as well as the relevance of appropriate consistent follow-up schedule for viral response during therapy. The first choice of therapy in chronic HBV infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Lamivudine is no longer the first choice; patients currently taking lamivudine must switch if the response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection.

AB - Diagnosis and treatment of hepatitis B virus (HBV) and hepatitis D virus infection mean for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while the society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms from 22 September 2017 set by a consensus meeting of physicians involved in the treatment of these diseases. The prevalence of HBV infection in the Hungarian general population is 0,5-0,7%. The indications of treatment are based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for a costeffective approach, the guideline stresses the importance of quick and detailed virologic evaluations, the applicability of transient elastography as an acceptable alternative of liver biopsy in this regard as well as the relevance of appropriate consistent follow-up schedule for viral response during therapy. The first choice of therapy in chronic HBV infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Lamivudine is no longer the first choice; patients currently taking lamivudine must switch if the response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection.

KW - Adefovir

KW - Cirrhosis

KW - Entecavir

KW - Hepatitis B virus

KW - Hepatitis D virus

KW - Interferon

KW - Lamivudine

KW - Liver cancer

KW - Pegylated interferon

KW - Tenofovir

KW - Viral hepatitis

UR - http://www.scopus.com/inward/record.url?scp=85042538459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042538459&partnerID=8YFLogxK

U2 - 10.1556/650.2018.31004

DO - 10.1556/650.2018.31004

M3 - Article

VL - 159

SP - 24

EP - 37

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

ER -